|
Samuel
Lunenfeld
Research Institute
Mount Sinai Hospital
Joseph and Wolf Lebovic Health Complex
5-1013 25 Orde St.
Toronto ON M5T 3L9
Tel.:
416-586-8516
Fax.:
416-586-5993
► Send
Email
► Lab
Website
|
|
Dr. Rita Kandel
INVESTIGATOR
Dr. Rita Kandel is Chief of Pathology and Laboratory Medicine at
Mount Sinai Hospital, and leads a staff of over 200 professionals who
make up the Department. At Mount Sinai Hospital, our Pathology and
Laboratory Medicine team is moving towards molecular diagnostics, which
measures a patient’s DNA, RNA, or proteins to diagnose a disease, or a
predisposition to a disease, like breast cancer for example, or suggest
a treatment. Mount Sinai’s implementation of this type of diagnostic
approach positions the Hospital at the forefront of the emerging field
of personalized medicine. Personalized medicine will allow a patient to
receive the appropriate treatment at the right time for that
individual.
Dr. Kandel is also a clinician-scientist and Associate Member of
the Samuel Lunenfeld Research Institute. Her research pursuits follow
two investigative paths. First, Dr. Kandel is working towards
identifying biomarkers (a protein that can indicate a particular
biological condition) associated with bone and soft tissue tumours
(sarcomas). Dr. Kandel collaborates closely with Mount Sinai Hospital’s
clinical Sarcoma Unit, the largest of its kind in Canada, ensuring that
the scientific questions being pursued are closely aligned with patient
care needs. By identifying the biomarkers unique to these tumours,
doctors will be able to diagnose the cancer at an earlier stage,
resulting in better outcomes for patients.
The regeneration of musculoskeletal (bone and soft) tissue is Dr.
Kandel’s second research focus. Specifically, Dr. Kandel’s Lab is
attempting to build new tissues to replace human joints that are
damaged by injury or disease. In fact, Dr. Kandel is confident that by
incorporating and developing new principles and techniques of
regenerative medicine, her lab will be able to build a replacement
joint made from biological materials in approximately five years. This
means that a joint will no longer be replaced with a plastic or metal
replica, but with one built from a patient’s own tissue and
cells.
Dr. Kandel is a professor at the University of Toronto, is
cross-appointed to the Department of Surgery and Institute of
Biomaterials and Biomedical Engineering, and is the Head of the
Bioengineering of Skeletal Tissues Team, which consists of a
multidisciplinary group of investigators, including engineers,
biologists, stem cell biologists, and clinicians whose work focuses on
regenerative medicine.
|
